Source: Andrew Wynn
Optimistic Outlook for ImmunityBio, Inc. with a new price target set by H.C. Wainwright
ImmunityBio, Inc. (NASDAQ:IBRX), a pioneering biotechnology company, has been at the forefront of developing innovative immunotherapy treatments. Its flagship product, Anktiva, has been instrumental in the company’s growth, especially in the treatment of cancers that have failed to respond to traditional therapies. In the highly competitive landscape of the biotech industry, where firms are constantly striving to advance cancer treatment options, ImmunityBio’s success signifies its potential for future growth.
H.C. Wainwright, a leading investment bank, set a price target of $15 for IBRX on February 23, 2026, indicating a potential upside of 54.56% from its current price of $9.71. This optimistic outlook aligns with the company’s recent performance, which witnessed a 16% surge in stock price following its fourth-quarter earnings announcement. At present, the stock is priced at $9.72, indicating an increase of 11.67% or a $1.02 rise.
Role of Anktiva in ImmunityBio’s growth and success
A key driving force behind ImmunityBio’s success is its flagship product, Anktiva. In 2025, Anktiva reported an incredible 700% sales increase and a 20% quarter-over-quarter growth in the final quarter. Despite a negative earnings per share of $0.06, the company has demonstrated profitability improvement for three consecutive quarters. This progress has played an instrumental role in the stock quintupling in 2026, highlighting the positive developments within the company.
The Cancer BioShield platform and Anktiva biologic product are central to ImmunityBio’s strategy. These stimulate natural killer cells, cytotoxic T cells, and memory T cells, helping patients combat various cancers and diseases. The bulk of the company’s revenue comes from U.S. sales of Anktiva, particularly for bladder cancer cases unresponsive to Bacille Calmette-Guérin treatment.
Growth Potential and Market Confidence in ImmunityBio
IBRX’s market capitalization currently stands at approximately $9.57 billion, with a trading volume of 73.67 million shares. The stock price has fluctuated between $9.59 and $11 today, with a 52-week high of $11 and a low of $1.83. These figures underscore the company’s growth potential and reflect the market’s confidence in its innovative cancer treatment solutions.
As the biotech industry continues to expand with new advancements in cancer treatment options, companies like ImmunityBio that are focused on innovation and growth are likely to thrive. The impressive sales figures of Anktiva, the flagship product of ImmunityBio, indicate the company’s resilience and ability to grow despite the challenges in the market.
Conclusion
The optimistic price target set by H.C. Wainwright for ImmunityBio, coupled with the company’s strong performance, reiterates the potential for growth and success in the biotech industry. The market’s confidence in ImmunityBio, as reflected by its market capitalization and high trading volume, strengthens the favorable outlook for the company. As ImmunityBio continues to innovate and improve its product offerings, it is positioned to further solidify its standing in the market and deliver strong returns for its shareholders.